"L’hôpital Ambroise-Paré est un hôpital de l’AP-HP situé à Boulogne-Billancourt, dans les Hauts-de-Seine (92). Centré sur la phase aiguë et ambulatoire des soins, il propose une large gamme de spécialités pour l’adulte et l’enfant. Alliant activités d’excellence et soins de proximité, notamment avec ses urgences adultes et pédiatriques, l’hôpital assure une prise en charge en chirurgie orthopédique, en cancérologie (dermatologie, cancers digestifs, pneumologie, oncogériatrie) en complémentarité avec l’Institut Curie – René Huguenin, mais également sur un large panel de disciplines médicales spécialisées. Il accueille également trois centres de référence spécialisés en nutrition clinique, infections ostéo-articulaires et maladies rares."

During the past decade, Hôpital Ambroise Paré conducted 96 clinical trials. In the 10-year time frame, 96 clinical trials started and 8 clinical trials were completed, i.e. on average, 8.3% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 4 clinical trials were completed. i.e. 8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Ambroise Paré" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 16 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 12 trials sponsored, "Hospital Ambroise Paré Paris" with 11 trials sponsored, "Intergroupe Francophone de Cancerologie Thoracique" with 10 trials sponsored and "Federation Francophone de Cancerologie Digestive" with 10 trials sponsored. Other sponsors include 113 different institutions and companies that sponsored additional 79 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Ambroise Paré" #1 collaborator was "Intergroupe Francophone de Cancerologie Thoracique" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Ministry of Health, France" with 3 trials as a collaborator and "Sanofi" with 3 trials as a collaborator. Other collaborators include 87 different institutions and companies that were collaborators in the rest 88 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Ambroise Paré" are "Colorectal Cancer" (11 trials), "Metastatic Cancer" (7 trials), "Pancreatic Cancer" (6 trials), "Melanoma" (5 trials) and "Carcinoma, Non-Small-Cell Lung" (4 trials). Many other conditions were trialed in "Hôpital Ambroise Paré" in a lesser frequency.

Most popular intervention types in "Hôpital Ambroise Paré" are "Drug" (96 trials), "Other" (29 trials), "Procedure" (26 trials), "Device" (14 trials) and "Biological" (13 trials). Other intervention types were less common.

The name of intervention was led by "fluorouracil" (13 trials), "Placebo" (12 trials), "leucovorin calcium" (11 trials), "adjuvant therapy" (7 trials) and "radiation therapy" (7 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Ambroise Paré" are 170 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hôpital Ambroise Paré". 3 are not yet recruiting, 40 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 84 completed trials in Hôpital Ambroise Paré, 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Ambroise Paré, 2 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 24 trials that are defined as “Not Applicable".